MarginsXMarginsX
Home › Markets › Health Care › LENZ

LENZ Therapeutics Inc. (LENZ)

LENZ trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.82
-7.51% on the day
Market cap
$120.0M
Micro cap
Revenue · 2025
$19.1M
Prior year not contiguous
Net income · 2025
-$82.1M
-430.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1815776/000181577626000011/0001815776-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerLENZ on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001815776
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$19.1M
Net income-$82.1M
Operating income-$91.1M
Net margin-430.3%
Operating margin-477.5%
Revenue growthNo prior-year revenue to compare
Cash$25.2M
Total assets$305.9M
P/E (computed)Net income was not positive
P/S (computed)6.3×

Warning signs

Cash runway
2.9 months
$30.6M cash at September 30, 2026
Share count, 1 year
+0.4%
2025-10-30 to 2026-10-28 · +279.2% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
$394K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$30.6M cash; operating cash flow -$31.9M a quarter.Report 2026-09-30
Shares outstanding31,420,583 (2026-10-28); 31,289,969 a year earlier; 57,996,481 three years earlier. 3y figure adjusted for split (1-for-7 overall).Cover page 2026-10-28
Reverse splits, 3 years1; latest 1-for-7 on 2024-03-22Source 2024-03-22
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-04-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $655K, sold $261K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$3.4M-$31.0M-$22.3M$30.6MNo debt tags$12.4M10-Q 2026-11-03
Q2 2026
2026-06-30
$5.5M-$31.9M-$38.7M$24.2MNo debt tags$21.5M10-Q 2026-08-11
Q1 2026
2026-03-31
$1.9M-$41.5M-$33.6M$24.8MNo debt tags$21.0M10-Q 2026-05-11
Q4 2025
2025-12-31
$1.6M-$35.9M-$33.0M$25.2MNo debt tags$19.1M10-K 2026-03-24
Q3 2025
2025-09-30
$12.5M-$16.7M-$8.6M$25.4MNo debt tagsNeeds four quarters10-Q 2026-11-03
Q2 2025
2025-06-30
$5.0M-$14.9M-$11.5M$37.6MNo debt tagsNeeds four quarters10-Q 2026-08-11
Q1 2025
2025-03-31
$0-$14.6M-$16.0M$23.0MNo debt tagsNeeds four quarters10-Q 2026-05-11
Q4 2024
2024-12-31
Not filed-$12.7M-$9.1M$20.2MNo debt tags$010-K 2026-03-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-04-14
Latest annual report10-K2026-03-24
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-10-28
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 359 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+18.0%
1 month+21.5%
3 months-10.2%
Year to date-74.2%
1 year-84.4%
From 52-week high-87.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
ARMPArmata Pharmaceuticals Inc.$2.99-22.74%$111.2M
ZURAZura Bio Limited$1.08-12.90%$104.0M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
VYGRVoyager Therapeutics Inc.$1.63-5.78%$101.4M
MOLNMolecular Partners AG$2.70-8.21%$101.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier